AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

mGlu5 Antagonist Pipeline Insight, 2019 Report Featuring Seaside Therapeutics, Allergan, Gedeon Richter, Novartis, & CT Laboratories - ResearchAndMarkets.com

April 9, 2019

DUBLIN--(BUSINESS WIRE)--Apr 9, 2019--The “mGlu5 Antagonist -Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

mGlu5 Antagonist - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across mGlu5 Antagonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for mGlu5 Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active mGlu5 Antagonist pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report

  • Provides a snapshot of the therapeutics pipeline activity for mGlu5 Antagonist
  • Features the mGlu5 Antagonist pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of mGlu5 Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across mGlu5 Antagonist

Key Topics Covered:

1. Report Introduction

2. mGlu5 Antagonist - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for mGlu5 Antagonist

4. Comparative Analysis

5. mGlu5 Antagonist Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. mGlu5 Antagonist Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Seaside Therapeutics
  • Allergan
  • Gedeon Richter
  • Novartis
  • CT Laboratories

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/k4zx0x

View source version on businesswire.com:https://www.businesswire.com/news/home/20190409005609/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/09/2019 08:31 AM/DISC: 04/09/2019 08:31 AM

http://www.businesswire.com/news/home/20190409005609/en